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Abstract
Tuberculosis (TB) treatment is hampered by the long duration of antibiotic therapy required to achieve cure. This indolent
response has been partly attributed to the ability of subpopulations of less metabolically active Mycobacterium tuberculosis
(Mtb) to withstand killing by current anti-TB drugs. We have used immune modulation with a phosphodiesterase-4 (PDE4)
inhibitor, CC-3052, that reduces tumor necrosis factor alpha (TNF-a) production by increasing intracellular cAMP in
macrophages, to examine the crosstalk between host and pathogen in rabbits with pulmonary TB during treatment with
isoniazid (INH). Based on DNA microarray, changes in host gene expression during CC-3052 treatment of Mtb infected
rabbits support a link between PDE4 inhibition and specific down-regulation of the innate immune response. The overall
pattern of host gene expression in the lungs of infected rabbits treated with CC-3052, compared to untreated rabbits, was
similar to that described in vitro in resting Mtb infected macrophages, suggesting suboptimal macrophage activation. These
alterations in host immunity were associated with corresponding down-regulation of a number of Mtb genes that have
been associated with a metabolic shift towards dormancy. Moreover, treatment with CC-3052 and INH resulted in reduced
expression of those genes associated with the bacterial response to INH. Importantly, CC-3052 treatment of infected rabbits
was associated with reduced ability of Mtb to withstand INH killing, shown by improved bacillary clearance, from the lungs
of co-treated animals compared to rabbits treated with INH alone. The results of our study suggest that changes in Mtb
gene expression, in response to changes in the host immune response, can alter the responsiveness of the bacteria to
antimicrobial agents. These findings provide a basis for exploring the potential use of adjunctive immune modulation with
PDE4 inhibitors to enhance the efficacy of existing anti-TB treatment.
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Introduction
Despite effective chemotherapy available for over 50 years, and
developmentofa controlstrategyofdirectlyobservedtherapyshort-
course (DOTS), tuberculosis (TB) remains the leading cause of adult
mortality attributable to a single infectious disease [1]. M. tuberculosis
(Mtb), the causative agent of TB, is an intracellular pathogen that is
well adapted to survive in host phagocytes within lung granulomas
inhumans andexperimentallyinfected animals[2–4].The outcome
of Mtb infection is largely determined by a delicate balance between
the host immune response and bacterial evasion and/or subversion
of this response, resulting in successful control of the infection or
manifestations of active disease of different severity [5,6]. In the
presence of an optimal host immune response, growth of the
infecting Mtb is controlled efficiently and the bacilli often cannot be
detected in infected tissues by the conventional colony-forming unit
(CFU) assay. However, during growth arrest, not all the infecting
bacilli are necessarily killed. Rather, they can adapt to survive in a
viable latent state, serving as a reservoir for potential reactivation
TB in the host, when immunity weakens [7–10]. Following Mtb
infection of a host with a suboptimal immune response, the bacilli,
internalized into the phagosomeof macrophagesand dendritic cells,
replicate and grow [11,12]. Within the phagosome, Mtb must resist
the bactericidal molecules of the host cell, including abundant
reactive oxygen (ROS) and nitrogen species (RNS), hydrolytic
enzymes and an acidic pH [13–15]. The invading bacteria
counteract this hostile host environment by dampening the process
of phagosome maturation, inhibiting lysosome-phagosome fusion
and limiting acidification, and shifting from a reliance on high
oxygen and a predominantly carbohydrate carbon source for
growth. Several mycobacterial genes involved in the bacterial
response to phagosomal stresses, such as hypoxia, starvation, iron
depletion, acid shock and alternate carbon metabolism, have been
reported to contribute to the metabolic adaptation of the bacteria to
intracellular survival and growth [16].
Activation of the immune response following Mtb infection
affects the expression of many host genes that are involved in the
production of cytokines, chemokines, surface receptors, and
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early changes affect subsequent cellular events, including extrav-
asation of leukocytes from the circulation, migration of immune
cells to affected tissues and lymphoid organs, and proliferation of
effector cells of the innate and adaptive immune response, in an
orchestrated response to fight the infection [18–20]. An association
between the level of macrophage activation and Mtb intracellular
survival has been reported previously [12,21]. In particular, RNS
produced by activated macrophages inhibit the growth of Mtb and
have been implicated as an environmental cue directing the
physiologic shift of the bacilli towards a state of dormancy
[10,22,23]. Thus, both the host cells and the bacilli alter their gene
expression during Mtb infection. However, the specific nature and
the interdependence of these events, and the links between the
host-pathogen crosstalk and the outcome of Mtb infection, are not
fully understood.
Tumor necrosis factor-alpha (TNF-a), produced by activated
macrophages and other cells of the immune system, is required for
the protective host response against Mtb infection. This inflam-
matory cytokine renders the macrophages more capable of
controlling the growth of or killing intracellular Mtb [24–26]. In
addition, TNF-a plays a vital role in coordinating and driving the
host inflammatory response [27]. While complete inhibition of
TNF-a production results in exacerbation or reactivation of TB in
animals and humans, excessive TNF-a levels can lead to severe
inflammation and damage to host cells and tissues [28,29]. Since
intracellular cyclic AMP (cAMP) regulates TNF-a production, the
total cellular TNF-a level and the resulting tissue inflammation are
determined in part by the level of this molecule [30]. Conse-
quently, agents that increase cellular cAMP levels have anti-
inflammatory properties [31–33]. Consistent with these findings,
inhibitors of PDE4 (PDE4i) that increase cellular cAMP levels
have been shown to reduce TNF-a production and dampen
inflammation [34–36].
Pharmacologic inhibition of TNF-a production has recently
been considered as a therapeutic modality in inflammatory
diseases [37–39]. Inhibition of TNF-a production by thalidomide
treatment in vivo and in vitro has been reported earlier [40,41].
Additional studies have shown that thalidomide treatment, in
combination with antibiotics, reduces TNF-a production in
patients with pulmonary TB and can improve treatment outcome
[42]. To avoid the side effects of thalidomide, analogs of the drug
have been synthesized and screened for their safety and TNF-a
inhibitory capacity [43,44]. One class of synthetic compounds acts
as effective PDE4i, which reduce TNF-a production by increasing
intracellular cAMP levels. These PDE4i are non-emetic, non-
teratogenic, and several of them have been found to be well
tolerated by humans in Phase I and II clinical studies [45]. One of
these PDE4i, used in the present study, CC-3052, is water soluble,
more stable in human plasma and ,200-fold more potent in
reducing TNF-a production, compared to the parent drug [46]. In
peripheral blood mononuclear cells (PBMC), the effect of CC-
3052 on TNF-a inhibition is dose-dependent [46]. Importantly, at
pharmacologically active doses, CC-3052 affects mainly monocyte
and macrophage TNF-a production, i.e. the innate immune
response, and does not have a significant effect on T cell
activation, suggesting a highly cell-specific mechanism of action
[47–49].
Isoniazid (INH) is one of the first-line antibiotics used in TB
treatment. Though INH efficiently kills actively growing Mtb,
dormant and non-replicating bacilli are killed only poorly
[50,51]. This observation has been reported in humans, mouse
and guinea pig models of experimental pulmonary TB, as well as
in vitro, using broth culture and Mtb infected macrophages
[52,53]. Exposure to INH results in the expression of a number
of Mtb genes involved in multiple stress and/or toxic responses
[54–56]. In addition, a specific group of INH-responsive Mtb
genes, involved in fatty acid metabolism and cell wall
biosynthesis, have been reported to be differentially expressed
between actively growing versus dormant bacilli, during acute
and chronic mouse infection, respectively [57]. These findings
highlight the close links between the regulation of Mtb gene
expression, bacterial metabolism and the response of the bacilli
to INH treatment.
As mentioned above, activation of macrophages by Mtb
infection creates a more hostile intracellular environment for
the bacilli to survive and grow [18–20]. It has been postulated
that robust macrophage activation drives a sub-population of
infecting organisms into a metabolic state that is recalcitrant to
antibiotic killing [10,22,23]. Consequently, we hypothesize that
dampening macrophage activation will alleviate the stress on the
intracellular bacilli, thereby creating a more permissive environ-
ment for bacterial metabolism, resulting in improved efficacy of
antibiotic killing. To test this hypothesis, using a rabbit model of
pulmonary Mtb infection, we examined the impact of CC-3052
treatment on the interactions between the host and pathogen, as
revealed by the changes in the expression of host and pathogen
genes. We used the rabbit model because, upon Mtb infection,
rabbits develop progressive pulmonary cavitary TB that, in
contrast to the mouse, is similar to the pathologic process seen in
humans. We determined which immune response genes in the
infected rabbit were specifically affected by treatment with CC-
3052. In addition, we evaluated corresponding changes in the
expression profile of bacterial genes, with particular emphasis on
the stress and INH response genes. Finally, we examined the
impact of CC-3052 treatment on bacillary load in the lungs of
Mtb infected rabbits with and without INH co-treatment. The
results of our study provide data to support the idea that
combining anti-TB drugs with an adjunctive immune modulator
may enhance the efficacy of current TB therapy regimens and
shorten the duration of treatment if applied appropriately to
humans.
Author Summary
Tuberculosis (TB) caused by Mycobacterium tuberculosis
(Mtb) is a leading infectious cause of morbidity and
mortality. Although current antibiotic regimens can cure
TB, treatment requires at least six months for completion.
Recent studies indicate that bacteria in a less metabolically
active state are less responsive to antibiotic killing and
suggest that this may partly explain the long duration
required for TB treatment. In this study, using a rabbit
model of pulmonary TB, we show that immune modula-
tion of Mtb infected animals with CC-3052, a phosphodi-
esterase-4 (PDE4) inhibitor that reduces tumor necrosis
factor alpha (TNF-a) production by increasing intracellular
cAMP levels, resulted in the down-regulation of host genes
involved in the innate immune response. Bacteria from the
lungs of CC-3052 treated rabbits displayed differential
expression of those genes associated with stress respons-
es. In addition, co-treatment of INH with CC-3052
abolished the INH-induced Mtb gene expression in the
infected rabbits. Importantly, bacillary clearance from the
lungs of rabbits co-treated with CC-3052 and INH was
improved over that in animals treated with INH alone. The
results of this study provide a basis for novel use of
immune modulation to improve the efficacy of antibiotic
therapy and to shorten the duration of TB treatment.
Adjunctive Immune Modulation Improves TB Therapy
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Effect of CC-3052 treatment on differential host gene
expression in Mtb infected rabbit lungs
Owing to the current paucity in immunologic reagents to
analyze the cellular function and soluble mediators of immunity in
rabbits, we used microarray technology to investigate the rabbit
immune response to pulmonary Mtb infection. Ingenuity Pathway
Analysis (IPA) was used for functional classification and pathway
construction of differentially expressed rabbit genes during Mtb
infection and CC-3052 treatment. Since an annotated rabbit
genome database for functional analysis is currently unavailable,
we utilized the homologues of rabbit genes from the annotated
human, mouse and rat genomes available in the IPA knowledge
base for our analysis. Rabbits were infected with Mtb by the
respiratory route, and the development of the host immune
response in the lungs was evaluated at 4, 8 and 12 weeks post-
infection using microarrays (Table 1). Of the 43,603 oligonucle-
otide probes represented on the rabbit array and analyzed by
global gene expression patterns, 5,332 were significantly differen-
tially expressed (3,075 up; 2,257 down) in response to 4 weeks of
Mtb infection of the lungs, compared to uninfected, naı ¨ve animals
(significant change defined as 62 fold with p#0.05). Progressive
up-regulation of host genes was noted as the infection progressed
for 8 weeks and 12 weeks, with 8,597 (5,344 up; 3,253 down) and
13,783 (4,260 up; 9,523 down) genes differentially regulated,
respectively. It is important to note that with time, as the
granulomas mature and differentiate following Mtb infection in
rabbit lungs, the profile of gene expression also changes. In
addition, of the total number of differentially regulated genes only
a subset overlap (1,269, 5,212 and 1,584 genes respectively for 4
vs. 8, 8 vs. 12 and 4 vs.12 weeks, data not shown), consistent with
the histologic observation of heterogeneity of the differentiating
granulomas [58].
CC-3052 treatment was started at 4 weeks post-infection, and
lung tissue was collected after 4 and 8 weeks of treatment (i.e. at 8
and 12 weeks post-infection). To study the changes in host gene
expression induced by CC-3052 treatment, we compared the gene
expression profiles in the Mtb infected lungs of CC-3052 treated
rabbits to untreated infected control animals at the same time
points. The complete list of rabbit genes differentially expressed by
CC-3052 treatment at the time points tested has been submitted to
the Gene Expression Omnibus (GEO) database (GSE27992).
Among the rabbit genes differentially expressed by Mtb infection,
statistically significant changes in the expression of 1,055 (34 genes
up; 1,021 down) and 1,272 (117 genes up; 1,155 genes down)
genes were observed after 4 and 8 weeks of CC-3052 treatment,
respectively (Table 1). Expression of 20 overlapping genes was
affected at both 4 (1 up; 19 down) and 8 weeks (9 up; 11 down) of
CC-3052 treatment. The distribution, among various cellular
immune response pathways, of the genes differentially expressed in
response to 4 and 8 weeks of CC-3052 treatment, is shown in
Table 2. About 30% of the genes differentially expressed following
4 weeks of CC-3052 treatment, compared to no treatment, were
involved in host immune response-related pathways. These
included immune cell growth and proliferation, cell morphology
and movement, cell death/apoptosis, immune cell trafficking and
hematologic development and function (Table 2). At 8 weeks of
Table 1. Number of differentially expressed host genes in Mtb infected rabbit lungs with or without CC-3052 treatment.
Number of differentially expressed genes*
Time p.i. (wk) CC-3052 treatment (wk) Total Up Down
4 0 5332 3075 2257
8 0 8597 5344 3253
8 4 1055 34 1021
12 0 13783 4260 9523
12 8 1272 117 1155
*Selected with a cut-off of +/22 fold and p#0.05 among 43,603 probes in the microarray slide.
doi:10.1371/journal.ppat.1002262.t001
Table 2. Classification of differentially expressed host genes in Mtb infected rabbit lungs treated with CC-3052.
Number of genes affected
4w CC-3052 (8wpi) 8w CC-3052 (12wpi)
Function/Pathway Total Up Down Total Up Down
Cell Growth/Proliferation 64 15 49 72 11 61
Cell Death 61 12 49 64 10 54
Molecular Transport 34 13 21 54 6 48
Tissue Morphology/Development 75 12 63 37 8 29
Hematologic Development/Function 43 17 26 46 6 40
Immune Cell Trafficking 31 10 21 33 6 27
Respiratory Disease 29 9 20 33 9 24
Cell Signaling/Interaction 43 18 25 38 8 30
doi:10.1371/journal.ppat.1002262.t002
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in immune cell growth/proliferation, cell death, molecular trans-
port, hematologic development/function, cell trafficking, were
modulated compared to 4 weeks of treatment. In contrast, the
number of rabbit genes involved in tissue morphology/develop-
ment and immune cell signaling/interaction were reduced at 8
weeks compared to 4 weeks of CC-3052 treatment. In summary,
the microarray analysis reveals differential expression of many host
genes during Mtb infection in the rabbit lung as well as the
modulation of a subset of those genes, involved in key host
immune response pathways, following CC-3052 treatment.
Modulation of the TNF-a network genes by CC-3052
treatment in Mtb infected rabbit lungs
Since inhibition of PDE4 reduces TNF-a expression, a key
regulator of innate and acquired immunity, we studied the effect of
CC-3052 treatment on the genes of the TNF-a network. The
expression patterns of a subset of genes that directly regulate or are
regulated by TNF-a,i nMtb infected rabbit lungs, at 0, 4 and 8
weeks of CC-3052 treatment were analyzed by microarray and
compared to levels of expression in lungs of infected untreated
animals (Figure 1). The fold changes in gene expression between
CC-3052 treated and untreated animals were used for the
pathway construction using IPA. In order to determine absolute
expression levels, we set no cut-off values for the expression levels
of individual genes in the network.
In the untreated rabbits, Mtb infection up-regulated more than
half of the genes (18 out of 32) in the TNF-a network, including
TNF-a itself (Figure 1A). Only 14 out of 32 genes were down-
regulated at 4 weeks post-infection compared to uninfected,
control rabbits. After 4 and 8 weeks of CC-3052 treatment, the
level of expression of the majority of these genes, specifically those
involved in tissue inflammation and the innate immune response,
including TNF-a, were progressively reduced (about 54% of genes
at 4 weeks and 75% at 8 weeks of CC-3052 treatment) compared
to untreated animals (Figure 1B). Not all of the genes in the TNF-a
network were affected by CC-3052 treatment. Eight genes that are
indirectly related to the TNF-a network (CD1c, CD1e, FMO-1,
EXT-1, MGST-3, and SERPIN-D1) were expressed at comparable
levels in untreated and CC-3052 treated, infected rabbits at 4 and
8 weeks post-treatment. Overall, the expression pattern of key
genes of the TNF-a network impacted by CC-3052 treatment
suggests a gradual reduction in the activation of the TNF-a
network in the lungs of Mtb infected rabbits.
Effect of PDE4 blockade on expression of representative
host genes in Mtb infected rabbit lungs
To evaluate the impact of CC-3052 treatment on the expression
of host genes associated with PDE4, the target of CC-3052, we
analyzed mRNA levels from the lungs of Mtb infected rabbits by
quantitative real-time PCR (qRT-PCR) (Figure 2). At 4 weeks
post-infection, low basal levels of expression of TNF-a and PDE4A
were noted in comparison with uninfected animals. TNF-a mRNA
levels increased to about 30- and 45-fold, respectively, in response
to 8 and 12 weeks of infection, but were not significantly different
between these two time points. The expression of PDE4A was
similarly elevated at 8 weeks and was somewhat lower at 12 weeks
post-infection. Treatment of infected rabbits with CC-3052 (for 4
or 8 weeks) significantly reduced the expression levels of both TNF-
a and PDE4A (Figure 2). On the other hand, while the lungs of Mtb
infected animals showed lower PKA expression at all time points in
comparison with uninfected controls, CC-3052 treatment reversed
this effect significantly, leading to about 3-fold higher levels of PKA
mRNA at 4 and 8 weeks of treatment (i.e. 8 and 12 weeks post-
infection) (Figure 2).
We then evaluated by qRT-PCR the mRNA levels of a subset of
genes, including cytokines (IFN-c, IL10, IL13, IL6 and TNF-b),
growth factors, chemokines and their receptors (CXCR3, GMCSF,
MIF and CCL4), signaling molecules and receptors (NFkB,
APRIL1, PI3K3 and TLR2) and intracellular trafficking and
apoptosis-related genes (RAB7, LAMP2, BCL-X, FAS and RAB11)
(Figure 3A and B). Many of these gene products are known
markers of macrophage activation and maturation, endosomal
trafficking and/or Th1/Th2 immunity [59–60]. In untreated
rabbits, most of these genes were progressively induced by Mtb
infection from 4 to 8 weeks, and many had reached a plateau (IFN-
c, IL13, IL6, MIF, CCL4, NFkB, APRIL, TLR2, RAB7 and LAMP2)
or were even reduced (IL10, CXCR3, GMCSF and PI3K3)b y1 2
weeks post-infection. In contrast, expression of the anti-apoptotic
gene BCL-X was progressively down-regulated by infection, and
there were no significant changes in the expression of other
selected genes, including TNF-b and RAB11 (Figure 3A and B).
Following 4 or 8 weeks of CC-3052 treatment, the expression of
many of these same genes were significantly reduced in
comparison to Mtb infected untreated animals. The expression
of genes that were not regulated by Mtb infection, for example
RAB11 and TNF-b, were also unaffected by CC-3052 treatment
(Figure 3). In summary, the expression profile of the host immune
response genes in the lungs of Mtb infected rabbits suggests that
CC-3052 treatment of rabbits with pulmonary TB resulted in a
dampening of macrophage activation in the lungs.
Effect of CC-3052 treatment on Mtb gene expression in
infected rabbit lungs
We analyzed the impact of CC-3052 treatment on gene
expression of the infecting bacilli. Total RNA from Mtb isolated
from infected rabbit lungs was prepared, and the expression levels
of selected hypoxic/oxidative stress response genes (narX, narK2,
devR, sodA and sodC) were evaluated by qRT-PCR. Expression of
these genes was induced progressively in the rabbit lungs from 4 to
12 weeks post-infection, with the exception of narK2 which reached
a plateau after 8 weeks (Figure 4), consistent with our observation
of progressive activation of macrophages in the granulomas. This
notion is also supported by previous demonstrations that rabbit
granulomas are hypoxic [61] and exposure of Mtb to hypoxia
differentially regulates several genes of the dosR regulon [62,63].
Treatment of Mtb infected rabbits with CC-3052 significantly
reduced the expression of narX, narK2, devR, sodA and sodC from 5-
to 150- folds (p,0.05), compared to infected but untreated
animals. These results are consistent with our hypothesis that CC-
3052-mediated reduction in macrophage activation would be
accompanied by changes in the extent of the Mtb stress response
during intracellular survival (Figure 4). However, treatment of log-
phase Mtb culture with equimolar amount (compared to in vivo) of
CC-3052 had no impact on the mRNA levels of these and other
dormancy/stress response-related Mtb genes, compared to un-
treated controls (Supporting Information Figure S1), indicating
that the effect of CC-3052 on Mtb gene expression was specific to
the in vivo conditions.
Recently, a comprehensive analysis of the gene expression
profiles of Mtb isolates, representing diverse lineages, grown in
vitro within activated and resting murine macrophages was
reported [64]. We selected for study a subset of genes from the
Homolka et.al. report, including genes previously reported as
differentially expressed by Mtb in response to environmental
stresses, such as metabolic adaptation to dormancy [65,66]. The
genes were functionally grouped as follows: a) protein synthesis
Adjunctive Immune Modulation Improves TB Therapy
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mbtF, mbtH, mbtE, mbtD, mbtC, mbtG, mbtA, mbtB and bfrA); c) cell
wall/lipid metabolism (ppsD, drrA, papA5, dfrA, fbpB, pckA, lipF,
mmpL8, pcaA, tgs1, icl and drrC); d) general stress response (hspX,
sigF, sigH, dnaE2, relA, mprA, groEL1, groEL2, groES and dnaJ); e)
ESX-3/secretion system (Rv0284-Rv0286, Rv0289, Rv0290 and
Rv0292); and f) histone-like proteins (hns and lsr2) (Figure 5).
Comparative gene expression profiling revealed that many of the
Mtb genes involved in protein synthesis, ESX-3/secretion, iron
metabolism and histone-like proteins were up-regulated by 4
weeks of CC-3052 treatment in rabbit lungs (Figure 5). In contrast,
many of the general stress response and cell wall/lipid metabolism
associated genes were down-regulated by CC-3052 treatment.
When the Mtb gene expression pattern from the lungs of CC-3052
treated rabbits was compared to the functional classifications of
Homolka et.al., the bacteria from the rabbits showed a gene
expression profile closer to that seen in resting, rather than
activated, macrophages (Figure 5) [13,64,67]. Thus, our functional
analysis of the Mtb gene expression profile in the lungs of infected
rabbits during CC-3052 treatment suggested that the bacilli were
in a different metabolic state than in the lungs of untreated, control
rabbits, and that this metabolic state corresponded with that
observed in suboptimally activated macrophages.
Effect of CC-3052 treatment on INH-mediated Mtb killing
in infected rabbit lungs
To study the effect of CC-3052 treatment on the ability of INH
to kill Mtb in the lungs of infected rabbits, animals were treated
from 4 weeks post-infection with high dose INH (50 mg/kg body
weight/day) or CC-3052 (25 mg/kg body weight/day), neither or
both for 4 or 8 weeks (i.e., 8 or 12 weeks post-infection). In the
untreated animals, implantation of about 3.2 log10 bacilli (on day
0) into the lungs resulted in progressive, active disease with
exponential bacterial growth up to 4 weeks of infection, after
which the bacterial counts stabilized and then declined slightly.
The control of bacillary load in the lungs of rabbits was not
significantly affected by CC-3052 treatment, as indicated by the
similar numbers of CFU in untreated and CC-3052 treated
animals at all time points tested (Figure 6). There were also no
significant differences in numbers of CFU in the liver and spleen
between these two groups (data not shown). INH treatment of
infected rabbits did not significantly reduce the CFU numbers in
the lungs of treated rabbits for the first 4 weeks. However, 8 weeks
of INH treatment (i.e. 12 weeks post-infection), the bacillary load
in the lungs was reduced by about 1 log10 (Figure 6).
The limited efficacy of INH monotherapy in Mtb infected
rabbits during the first 4 weeks prompted us to evaluate the
bioavailability of the drug. To assess the extent to which INH was
absorbed into the circulation, we measured the plasma INH
concentration in animals that received either 25 mg/kg or 50 mg/
kg of INH per day by gavage administration. Both doses of the
drug resulted in similar plasma levels up to 8 hours post-
administration (Figure 7A). However, only the 50 mg/kg dose of
INH resulted in detectable INH levels in the plasma up to
24 hours. To compare INH availability when administered in
drinking water to that of the gavage route of delivery, rabbits were
treated with 50 mg/kg of INH by either route, and the
pharmacokinetics of INH in the plasma were compared
(Figure 7B). The parameters for INH in drinking water were
calculated, assuming a steady state dosing during a 24-hour
interval. Compared to INH in drinking water, a single dose of
50 mg/kg of INH administered by gavage showed about 100-fold
increase in plasma drug levels within 2 hours of administration.
However, both routes of administration showed similar INH levels
in the plasma at 24 hours post-administration and similar
bioavailability, as measured by the area under the curve
(Figure 7B). This observation supported the use of gavage
administration for appropriate dosing of INH, thereby avoiding
the uncertainty of drug dosing through drinking water which arises
from the fact that rabbits do not consume reproducible volumes of
water daily.
When rabbits were treated with CC-3052 in combination with
INH for 4 weeks, a statistically significant reduction in the
numbers of CFU was noted, compared with INH alone (p=0.027,
Figure 6). An additional 4 weeks of co-treatment resulted in a 10-
fold reduction in bacillary load compared to INH alone (p=0.003,
Figure 6). Thus, while the rate of Mtb killing was similar during the
second month of treatment, the absolute numbers of CFU in CC-
3052 co-treated animals were significantly lower than in the INH
alone group by the end of experiment. It is important to note that
treatment of infected rabbits with INH alone or in combination
with CC-3052 for up to 2 months did not produce INH resistant
bacilli, as determined from the CFU assay by plating the lung
homogenates in the presence and absence of INH. The effect of
CC-3052, either alone or in combination with INH, on Mtb was
specific to the in vivo conditions present in the lungs of infected
rabbits, since the addition of up to 50X molar excess of CC-3052
and 0.2 mg/ml of INH (the minimal inhibitory concentration) to a
growing Mtb culture in vitro did not affect the growth or INH
killing significantly (Figure S2). Future experiments, including
prolonging the duration of treatment of infected rabbits (more
than 8 weeks) and varying the starting time of treatment, will
determine if combined administration of INH and CC-3052 can
fully eliminate the bacteria from rabbit lungs.
Effect of CC-3052 treatment on INH-mediated Mtb gene
expression in infected rabbit lungs
We next analyzed the impact of INH treatment on the
expression of INH-associated Mtb genes in the presence and
absence of CC-3052 in rabbit lungs (Figure 8). Total Mtb RNA
was isolated from the lungs of infected rabbits and analyzed by
qRT-PCR. Similar to results reported in several studies, after 4
weeks of INH treatment, we observed significant increases in the
mRNA levels of the Mtb genes, katG, ahpC, inhA, kasA, iniB and efpA
(Figure 8). [55,57,68]. There was no statistically significant
differences in the level of expression of fadD26 between Mtb
RNA pools from INH treated and untreated animals. The gene
induction profile was specific for INH treatment, since these genes
were not affected by treatment of similarly infected rabbits with
rifampicin (RIF), another important antibiotic for TB treatment
Figure 1. Differential expression of genes involved in the TNF-a network between untreated and CC-3052 treated, Mtb infected
rabbits. The absolute expression level of rabbit genes, from the microarray experiments on the lungs of Mtb infected and CC-3052 treated or
untreated rabbits, was used in Ingenuity Pathway Analysis (IPA) software program to construct pathway maps. (A) Pathway map of rabbit genes
regulating- or regulated by- TNF-a at 4 weeks (No CC-3052 treatment) The numbers at the bottom of each gene represent the absolute expression
levels. (B) Intensity plot of TNF-a network genes before (UT) or after 4weeks (4w-CC) or 8 weeks (8w-CC) of CC-3052 treatment. For both A and B,
green color represents down-regulation and red color represents up-regulation. The level of up- or down-regulation is related to the intensity of
respective colors.
doi:10.1371/journal.ppat.1002262.g001
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normalization to the 16S rRNA, ranged from 2- (for inhA) to about
20-fold (for katG and ahpC)( p#0.05) in comparison to levels
observed in untreated animals. The levels of expression of these
genes in the lungs of untreated and CC-3052 alone-treated
animals were comparable and significantly less than what was
Figure 2. qRT-PCR of rabbit genes that are directly related to the mode of action of CC-3052. Total host and bacterial RNA was isolated
from lungs of the rabbits from various treatment groups (mentioned in the Materials and Methods section) of Mtb infected and uninfected rabbits at
4, 8 and 12 weeks post-infection and used to enumerate the transcript levels in qRT-PCR experiments with gene specific primers. The difference in
specific gene expression was calculated as fold change in expression between CC-3052 treated vs. untreated or Mtb infected vs. uninfected rabbits at
each time point. The X-axis legend is common for all four figures. Changes in the rabbit gene expression by Mtb infection are represented as relative
fold change, compared to the levels in uninfected rabbit lungs, and normalized to housekeeping GAPDH levels. Results shown are mean 6 standard
deviation from at least 2 experiments done in duplicate (total of at least 4 data points) with samples from two to four animals per group per time
point. *Statistically significant difference between CC-3052 treated and untreated animals at the same time point (p#0.05).
doi:10.1371/journal.ppat.1002262.g002
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PLoS Pathogens | www.plospathogens.org 7 September 2011 | Volume 7 | Issue 9 | e1002262Figure 3. Effect of CC-3052 treatment on rabbit gene expression during Mtb infection. Total RNA isolated from the lungs of Mtb infected
and uninfected rabbits that were either treated with CC-3052 or left untreated were used to determine the abundance of transcripts using qRT-PCR
with gene specific primers. (A) Level of expression of rabbit genes encoding for cytokines (IFN-c, IL13, IL6, IL10 and TNF-b) and chemokines (CXCR3,
GMCSF, MIF and CCL4). (B) Expression level of rabbit genes encoding for intracellular signaling molecules (NFkB, APRIL1, PI3K3 and TLR2), endosomal
trafficking markers (RAB7, LAMP2 and RAB11) or apoptosis pathways (BCL-X and FAS) in the lungs of Mtb infected rabbits. Change in gene expression
levels in the CC-3052 treated rabbits were calculated as relative fold difference after normalization to the level of expression of the housekeeping
gene, GAPDH, and calibrated against the levels in uninfected or untreated animals. The difference in the level of expression of all tested genes
between CC-3052 treated (CC) and untreated (UT) animals were statistically significant (p#0.05) at 8 and 12 weeks post-infection except for the
following: TNF-bat 8 weeks and IFN-c at 12 weeks. Expression of RAB11 was not statistically different at both 8 and 12 weeks post-infection. The
results shown are mean 6 standard deviation from at least 2 experiments done in duplicate (total of at least 4 data points) with samples from two to
four animals per group per time point.
doi:10.1371/journal.ppat.1002262.g003
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of INH treatment of infected rabbits did not reduce the bacillary
load significantly, exposure to the antibiotic clearly affected the
physiology of the infecting bacteria, as manifested by differential
gene expression, consistent with previous reports [7,8,55,57,68].
Interestingly, co-treatment with INH plus CC-3052 reduced the
expression of INH–induced genes in Mtb to levels similar to those
observed in untreated rabbit lungs.
Discussion
In the present study, we describe the effect of PDE4 inhibition on
the immune response during Mtb infection in a rabbit model of
pulmonary TB and show how changes in the expression of immune
response genes affect the crosstalk between the host and pathogen
(Figure 9). During the course of Mtb infection in the lungs of
untreated rabbits, expression levels of many host genes involved in
the innate immune response were up- regulated. Corresponding
changes were observed in the expression of many Mtb genes known
to be responsible for successful intracellular survival of the bacilli,
including genes involved in protecting the bacteria against ROS-
and RNS-induced damage and bacillary response to stress induced
by nutritional deprivation and acid shock. These genes were up-
regulated gradually with disease progression in the lungs of
untreated, Mtb infected rabbits. Treatment of the Mtb infected
rabbits with CC-3052 led to significantly reduced expression of
many of the host innate immune response genes, including TNF-a
and IL-6. Concomitant with these PDE4-induced changes in host
gene expression, the levels of expression of many bacterial stress
response genes were reduced.
Importantly, CC-3052 treatment of infected rabbits was
associated with a loss in the ability of the bacilli to withstand
INH killing, and bacillary clearance was improved starting from
the first month of treatment compared to INH alone. These results
contrast with our previously reported study in the murine TB
infection model [49], in which we showed that co-treatment with
CC-3052 extended the duration of INH-mediated bacillary
clearance from the lungs at later time points, when INH effe-
ctiveness began to fail, but did not significantly affect the CFU
numbers during early treatment [49]. The differences in the
kinetics of improved INH-mediated Mtb clearance from the lungs
in the presence of immune modulation likely reflect differences in
the pathogenesis of Mtb infection in these two animal models.
While rabbit lungs develop fully matured granulomas by 4 weeks
post-infection that progress to necrotizing granulomas and cavities,
similar to humans, the mouse immune response to Mtb infection
involves the accumulation of mononuclear leukocytes that do not
differentiate into structured granulomas [69]. Our observations
suggest that, in the rabbit, INH fails to kill the bacilli efficiently in
the early well-differentiated granulomas of the lungs (4 to 8 weeks
post-infection). Moreover, CC-3052 co-treatment improves INH-
mediated bacillary clearance at these early time points. Thus, in
the present study, we have demonstrated the effect of PDE4
inhibition on Mtb killing within a mature granuloma, in contrast
to our findings in the mouse, where the impact of immune
modulation was observed on residual persisting bacilli towards the
end of treatment. It is possible that, in the rabbit model, CC-3052
treatment would further improve Mtb killing at later time points
(after 12 weeks) when INH alone fails to kill persisters. Indeed, it
has been reported that the proportion of physiologically quiescent
Figure 4. Effect of CC-3052 treatment on the expression of Mtb stress response genes in rabbit lungs. Total Mtb RNA was isolated from
the lungs of rabbits from various treatment groups (mentioned in the Materials and Methods section) of Mtb infected rabbits at 4, 8 and 12 weeks
post-infection and used to quantify the amount of transcripts in qRT-PCR experiments with primers specific for those Mtb genes that are involved in
the stress response. The values plotted in the graph are absolute transcript levels of each Mtb gene after normalization to 16S rRNA levels. The
mycobacterial genes represented in the graph are: narX- probable nitrate reductase; narK2- possible nitrate/nitrite transporter; devR- two component
transcriptional regulatory protein; sodA- superoxide dismutase A; sodC-superoxide dismutase C. The results are shown as mean 6 standard deviation
from at least 2 experiments done in duplicate (total of at least 4 data points) with samples from two to four animals per group per time point.
*Statistically significant difference between CC-3052 treated and untreated animals (p#0.05).
doi:10.1371/journal.ppat.1002262.g004
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response to INH treatment [70,71]. Hence, the differential
outcome of INH treatment with and without CC-3052 could be
attributed to changes in the metabolism of a sub-population of
bacilli [56,72]. This suggests the presence of a higher percent of
bacilli that are dormant and/or non-responsive to INH at 4 weeks
post-infection of the rabbit lung, compared to the mouse lung.
Since the nature and extent of the host immune response to Mtb
infection significantly affect the physiology of the infecting bacilli
[73], and rabbit granulomas are hypoxic and more mature
Figure 5. Effect of CC-3052 treatment on the expression of Mtb metabolic genes in rabbit lungs. Total Mtb RNA was isolated from the
lungs of rabbits from various treatment groups (mentioned in the Materials and Methods section) of Mtb infected rabbits at 8 weeks post-infection
and used to measure the transcript levels using qRT-PCR with primers specific for Mtb genes involved in various metabolic processes. The change in
Mtb gene expression is represented as relative ratio between untreated and CC-3052 treated samples, after the levels of expression of each gene was
normalized to 16S rRNA levels. Description of individual Mtb genes is included in Table S1. Results shown are average values from at least 2
experiments done in duplicate (total of at least 4 data points) with samples from two to four animals per group per time point.
doi:10.1371/journal.ppat.1002262.g005
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number of bacilli that are non-responsive to INH treatment in the
4-week rabbit granulomas may be relatively high. Taken together,
studies in the rabbit provided a useful model that is more similar to
human disease than the infection seen in the mouse lung.
The changes observed in host gene expression during CC-3052
treatment of Mtb infected rabbits support a link between PDE4
inhibition and specific modulation of the innate immune response.
So far, at least 11 families of class 1 PDEs (PDE1-11) have been
identified in humans [74]. However, only 3 of the 11 (PDEs 4, 7
and 8) are involved in hydrolyzing cAMP [75]. Of these, PDE4 is
the predominant isoform of phosphodiesterase found in mono-
cyte/macrophages [76]. Thus, inhibition of PDE4 would be
expected to target monocytes and macrophages, but not T cells
and other cells of the immune response. The ability of the rabbits
to control bacillary growth in the lungs in the presence of CC-3052
supports the conclusion that this drug does not suppress the
acquired immune response. Moreover, in our previous study, the
mouse TB model enabled us to directly demonstrate that CC-3052
does not inhibit T cell activation in Mtb infected animals [49].
PDE4 hydrolyses cAMP in the phagocyte, decreasing the levels of
this important second messenger, which regulates essential cell
signaling events that determine many cell functions [77,78].
Previous studies have shown that increased levels of cAMP
modulate immune cell functions, including the respiratory burst,
chemotaxis, phagocytosis and phagosome maturation [79,80].
Consistent with these findings, treatment of Mtb infected rabbits
with CC-3052 significantly reduced the steady state mRNA levels
of TNF-a and other pro-inflammatory, Th1 and Th2 cytokines,
chemokines and their receptors, apoptosis-associated genes,
surface receptors, and signaling molecules in macrophages.
TNF-a plays a central role in the host innate immune response
and specifically in the activation of macrophages [81]. This
cytokine is primarily regulated via TLR signaling through
activation of the NFkB pathway [82,83]. Thus, the reduced level
of expression of both the TNF-a and NFkB genes in the lungs of
Mtb infected rabbits treated with CC-3052 suggests a suboptimal
activation of macrophages in the lesions of these animals [84].
Suboptimal activation of macrophages has been shown to affect
the cellular organization in the lung granulomas of Mtb infected
animals [49]. Briefly, in Mtb infected animals, there were no
significant differences either in the total number of subpleural lung
granulomas or in the area of lung involved, between the untreated
and CC-3052 treated rabbits up to 12 weeks post-infection.
However, the granulomas in the lungs of CC-3052 treated rabbits
appeared less necrotic, less fibrotic and more cellular compared to
the untreated rabbits, most strikingly at 12 weeks post-infection (8
weeks of CC-3052 treatment). In mice, CC-3052 treatment
affected the distribution of T cells in the lung lesions without
affecting their total numbers. When Mtb infected animals (both
mice and rabbits) were treated with INH plus CC-3052, a
significant reduction in the size and number of lung granulomas
was noted, compared to INH treatment alone. Whether these
morphologic changes affected drug penetration and/or exposure
of the bacilli to INH in the granulomas is as yet unknown and will
be investigated in the future.
Macrophage activation during infection is associated with
phagosome maturation, as indicated by the acquisition of RAB7
Figure 6. Effect of CC-3052 and INH treatment on the growth of Mtb in rabbit lungs. Rabbits were infected with Mtb HN878 by aerosol
challenge to implant 3.2 log10 bacilli on day 0. Starting at 4 weeks post-infection, groups of rabbits were treated with CC-3052, INH, both or left
untreated, and treatment continued until 12 weeks post-infection. At 0, 4, 8 and 12 weeks post-infection, groups of 2–4 rabbits per treatment
condition, were necropsied and segments of lung tissue were homogenized and plated on 7H9 agar plates to enumerate the numbers of CFU
(detailed in the Materials and Methods section). The total numbers of CFU (in log10 scale) was calculated for the entire rabbit lungs. Rx represents the
starting time point (4 weeks) for CC-3052 and/or INH treatment. The experiment was repeated at least twice with 2–4 animals per time point per
treatment group. Results shown are means 6 standard deviation from 6–11 animals. *Statistically significant difference between untreated and INH
treated animals at 12 weeks post-infection (p,0.05). **Statistically significant difference between INH plusCC-3052- and INH alone- treated animals at
8 and 12 weeks post-infection (p,0.05).
doi:10.1371/journal.ppat.1002262.g006
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expression of RAB7 and LAMP2 in response to CC-3052 treat-
ment suggests that there may indeed have been impaired or
suboptimal macrophage phagosome maturation in the immune
modulated rabbits. In addition, macrophage activation during
Mtb infection is characterized by the production of a number of
pro-inflammatory cytokines, chemokines, growth factors and
their receptors. Increased TNF-a production by activated
macrophages leads to increased expression of apoptotic genes,
such as FAS, and reduced expression of anti-apoptotic gene
expression, such as BCL-X [60]. The reduced expression of FAS
and increased expression of BCL-X observed in rabbits treated
with CC-3052 suggests reduced cell apoptosis during treatment
with the PDE4i. Overall, the pattern of change in host gene
expression in the lungs of Mtb infected rabbits treated with CC-
3052, compared to untreated rabbits, was similar to that seen in
resting macrophages cultured in vitro, where expression of the
genes encoding for proinflammatory cytokines, chemokines, and
their receptors was relatively low [86–88].
The modulation of host innate immunity by CC-3052 treatment
appeared to be sensed by the infecting intracellular Mtb, resulting
in corresponding changes in the expression of many bacterial
genes. How would changes in macrophage activation be expected
to affect the physiology of the infecting bacilli? First, the
Figure 7. Pharmacokinetics and dynamics of INH uptake into the serum of treated rabbits. (A) Level of INH detected in the plasma of
rabbits treated with a bolus dose of either 25 or 50 mg/kg of INH by gavage. INH levels were estimated by HPLC-mass spectrometry as explained in
the Materials and Methods section (B) Effect of different modes of administration of INH on rabbit plasma INH levels. Rabbits were treated with INH
either by gavage using a rubber feeding tube, or in drinking water. Plasma INH from treated rabbits was separated from the blood collected at
indicated time points, post-administration, to measure the INH concentration by HPLC-mass spectrometry as explained in the Methods section. The
horizontal dotted line in (B) represents the optimal level of quantification of INH.
doi:10.1371/journal.ppat.1002262.g007
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genes induced during infection was significantly reduced by CC-
3052 treatment supports our hypothesis that Mtb adapted to
perturbations in the host environment [14,23,73,89–92]. The
metabolic shift-down of selected Mtb genes during non-replicating
persistence is mediated by the activation of devR, a global
transcriptional regulator, that up-regulates at least 53 Mtb genes
involved in the bacterial adaptation to dormancy [93,62]. Among
these are the Mtb stress response genes, narX and narK2, which are
induced when the infecting bacilli enter into dormancy [65,94,95].
In the present study, CC-3052 treatment reduced the expression of
devR, narX, and narK2 in the infected rabbit lungs, suggesting that
the bacilli sensed the reduction in environmental pressure within
suboptimally activated macrophages. Treatment with the PDE4i
also lead to reduced expression of the transcriptional regulator
relA, which is essential for Mtb survival under stress conditions, as
well as for infection, persistence and dissemination in mice and
guinea pigs [96,97]. Consistent with our findings, loss of relA
expression in Mtb has been shown to be associated with reduced
lung inflammation and pathology in infected guinea pigs [97].
Similarly, mycobacterial genes encoding superoxide dismutases
(sodA and sodC), heat shock protein (hspX) and stress response sigma
factors (sigF and sigH) have been shown to be associated with
adaptation of the bacilli to a stressful environment, such as
hypoxia, within activated macrophages [98–100]. The mRNA
levels of these mycobacterial genes (sodA, sodC, sigF and sigH) were
down-regulated during CC-3052 treatment, consistent with
adaptation of the bacilli to a less stressful environment. Differential
regulation of the sigma factors ensures the regulation of a distinct
set of Mtb genes essential for survival under various environmental
conditions such as availability of nutrients, oxygen status, and the
presence of antibacterial molecules. [101]. Moreover, the up-
regulation of a set of Mtb genes involved in protein synthesis, cell
wall/lipid metabolism, iron metabolism and ESX-3/secretion
pathways in response to CC-3052 treatment was similar to the
pattern observed for intracellular Mtb inside resting macrophages
[64]. Interestingly, cycloproponation of Mtb cell wall mycolates by
pcaA has been shown to be essential for the immune recognition of
Mtb through trehalose dimycolate (TDM), an inflammatory
glycolipid unique for pathogenic Mtb [102,103]. Furthermore,
lack of mycobacterial pcaA gene expression was shown to reduce
the level of TNF-a and other proinflammatory cytokines in Mtb
infected murine bone marrow macrophages [102]. Taken
together, the results of our study support the existence of mutually
regulated host-pathogen interactions during Mtb infection. Both
the infected host cells and the infecting bacilli appear to fine-tune
their gene expression during adaptation to a state of intracellular
infection. When the natural infection-induced macrophage
activation was dampened in CC-3052 treated animals, as
evidenced by the reduced expression of innate immune response
genes, the bacilli sensed the change and reset their metabolism by
altering their own gene expression.
Remarkably, changes in the gene expression profile of the
bacilli, albeit limited in magnitude, appeared to affect the ability of
INH to kill the bacteria. It is conceivable that, when the
transcriptional regulation of Mtb genes, such as those governed
by devR, relA and alternate sigma factors, associated with the
dormant/non-replicative state is altered, the bacilli are forced out
of the non-replicating, persistent drug tolerant state [104,105].
Thus, a change in the microenvironment wherein the infecting
Figure 8. Effect of CC-3052 treatment on the expression of Mtb INH responsive genes in rabbit lungs. Total Mtb RNA was isolated from
the lungs of rabbits from various treatment groups (mentioned in the Materials and Methods section) of Mtb infected rabbits at 8 weeks post-
infection and used to quantify the amount of transcripts by qRT-PCR with primers specific for those Mtb genes that respond to exposure to INH. The
difference in Mtb gene expression was calculated as relative ratio (in log10 scale) between untreated and CC-3052 treated rabbits, after the level of
expression of each gene was normalized to 16S rRNA levels. RIF represents samples from rabbits treated with rifampicin. The mycobacterial genes
represented in the graph are: katG- catalase-peroxidase-peroxynitritase; ahpC- alkyl hydroperoxidase C; inhA- NADH-dependant enoyl-ACP reductase;
kasA- beta-ketoacyl-ACP-synthase; iniB- isoniazid inducible gene; efpA- possible integral membrane efflux protein; fadD26- fatty acid CoA synthase.
Results shown are mean 6 standard deviation from at least 2 experiments done in duplicate (total of at least 4 data points) with samples from two to
four animals per group per time point. * Statistically significant difference between untreated and INH treated animals (p,0.05). ** Statistically
significant difference between INH plusCC-3052- and INH alone- treated animals (p,0.05).
doi:10.1371/journal.ppat.1002262.g008
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to antibiotic killing. Consistent with this hypothesis, we observed
improved bacterial killing in the lungs of Mtb infected rabbits
treated with INH plus CC-3052 compared to INH alone.
Increased expression of the INH-induced Mtb genes following 4
weeks of INH treatment was an indication of bacterial exposure to
INH, despite the minimal bactericidal activity observed at this
time point. In contrast, 4 weeks of INH treatment in the presence
of CC-3052 led to reduced levels of expression of these genes.
Though the exact mechanism of down-regulation of INH-
responsive Mtb gene expression during CC-3052 co-treatment is
currently unknown, this observation may be linked to the
improved killing of Mtb by INH plus CC-3052. The results of a
number of previously published studies may offer alternative non-
exclusive explanations for our findings. INH is a pro-drug that is
activated by the bacterial catalase-peroxidase (KatG) to form
functional adducts with NAD, which inhibit InhA, an important
enzyme involved in the cell wall synthesis of Mtb [106–107]. In
addition to INH activation, KatG also possesses peroxynitritase
and NADH oxidase activities that are vital for bacterial defense
against oxidative stress [108–109]. Thus, as we have observed in
the CC-3052 treated rabbits, under reduced oxidative stress
conditions, katG expression would be expected not to be up-
regulated. Furthermore, induction of mycobacterial efflux pumps
and their regulators, in response to intracellular stress conditions
during macrophage infection of Mtb, has been reported [110–
112]. Recently, increased expression of an efflux pump was
reported to be associated with tolerance of M. marinum to INH in a
zebrafish model of mycobacterial infection [113]. Moreover, up-
regulation of efpA, encoding for an efflux pump in Mtb, has been
reported in MDR-TB [114]. In the present study, the reduced
expression of efpA in CC-3052 treated rabbits may contribute to
the improved INH-mediated killing observed. Recently, by
screening a chemical library of 300 compounds for their inhibitory
activity against enoyl reductase (InhA), Vilcheze et.al identified
two potential targets, CD39 and CD117, that exhibited signifi-
cantly increased Mtb killing when combined with INH, compared
to treatment by either of the compounds separately or INH alone
[115]. This finding suggests that chemicals that reduce/inhibit
InhA could facilitate improved Mtb killing when co-administered
with INH. A similar mechanism may be operative in our studies
where inhibition of expression of inhA by CC-3052 treatment of
the rabbits was associated with an increase in INH-killing of Mtb.
Studies from our group and others have shown that generalized
immune suppression by anti-TNF-a antibody treatment in the
mouse model of pulmonary TB compromised the ability of the
animals to control bacillary growth, and exacerbated the
pathology in the lungs [84,116,117]. Unlike anti-TNF-a antibody
treatment and similar to our data in the mouse, CC-3052-
mediated PDE4 inhibition had no effect on bacillary growth in the
lungs of infected rabbits [49]. The use of PDE4 inhibition as a
means to reduce, but not abolish, TNF-a levels has the selective
advantage of targeting the level of production of the cytokine in
monocytes and macrophages. Thus, T cells and other cells of the
immune response would retain their ability to produce TNF-a,
facilitating control of Mtb infection in the lungs. In contrast,
Figure 9. Schematic representation of the mechanism by which CC-3052 treatment affects macrophage activation and improve
INH-mediated Mtb killing in the lungs of infected rabbits.
doi:10.1371/journal.ppat.1002262.g009
Adjunctive Immune Modulation Improves TB Therapy
PLoS Pathogens | www.plospathogens.org 14 September 2011 | Volume 7 | Issue 9 | e1002262complete neutralization of TNF-a production by treatment with
an antibody against the cytokine would be expected to render the
animals immune suppressed, thereby leading to uncontrolled
bacillary growth and death of the animals [118–121,94]. In
addition, in vitro culture of Mtb in the presence of CC-3052 had
no effect on the growth of the bacilli, confirming that the PDE4i
had no direct effect on bacillary growth or killing, but rather
affected the bacilli in vivo via modifying the host cell (Figure S2).
Thus, dampening innate immunity without interfering with the
development of the acquired immune response was associated with
changes in the metabolic activity of Mtb but not with loss of control
of bacillary growth. Previous reports have demonstrated the
usefulness of TNF-a inhibition by CC-3052 treatment, both in
acute and chronic HIV-1 infection in vitro [122,123]. In addition,
the safe administration of several PDE4i has been demonstrated in
clinical trials for the treatment of other inflammatory diseases,
including asthma and chronic obstructive pulmonary disease
[124–126]. An adjunctive therapeutic approach, such as the one
described in this study, could be used to treat humans with TB,
providing a means for shortening treatment and improving clinical
outcome in patients with active disease. The absence of significant
immune suppression or other toxicities supports the idea that such
an approach may safely contribute to improved treatment of TB.
Taken together, our observations support the hypothesis that
changes in the physiology of the bacteria, in response to changes in
the host immune response can alter the susceptibility of the
bacteria to antimicrobial agents. This is a novel strategy to combat
Mtb infection, facilitating the use of the existing drugs more
efficiently. As different anti-TB drugs target both overlapping and
diverse bacterial functions, it is important to evaluate immune
modulation during other single as well as multidrug treatments.
Currently we are testing this approach by combining CC-3052
with other anti-TB drugs in our rabbit model of pulmonary TB.
Materials and Methods
Ethics statement
All rabbit experiments were performed according to the
procedures and policies of the Animal Welfare Act guidelines for
housing and care of laboratory animals and conducted in
accordance with Public Health Service Policy Institutional regula-
tions. Animal ethics approval for rabbit aerosol infection with Mtb,
treatment, post-treatment care, euthanasia and necropsy was
obtained from the Institutional Animal Care and Use Committee
(IACUC) and Institutional Biosafety Committee (IBC) of the Public
Health Research Institute (PHRI) at University of Medicine and
Dentistry of New Jersey (UMDNJ) (IACUC approval numbers
070,124 and 125). All procedures with the infected animals/tissues
were performed in a Biosafety level three (BSL-3) containment
facilities according to the approved protocols.
Mycobacterial culture conditions and chemicals
Mycobacterium tuberculosis HN878 (Mtb) (a gift from Dr. Musser,
TX, USA), a member of Beijing strains, was grown to mid-log
phase (OD600=0.6–0.7) in Middlebrook 7H9 liquid media (Difco,
MI, USA) supplemented with 0.5% glycerol, 10% OADC
enrichment (oleic acid, albumin, dextrose and catalase; BD
Biosciences, MD, USA) and 0.25% Tween 80 at 37uC and 5%
CO2 as static culture. The culture was gently mixed once a day for
proper aeration. Serial dilutions of the culture were enumerated
for the number of colony forming units (CFU) by plating on 7H10
agar plates (Difco, MI, USA) followed by incubation of the plates
at 37uC and 5% CO2 for 4–5 weeks. All the stock cultures were
stored as aliquots at 280uC until use. A vial of frozen stock culture
was thawed at 37uC, sonicated three times in 5-seconds pulses on
ice to disrupt bacterial clumps, diluted to 5610
6 CFU/ml in sterile
saline with 0.05% Tween 80 and used for rabbit aerosol infection
[127]. The PDE4 inhibitor used in this study, CC-3052, was a
kind gift from Celgene Corporation (Celgene Corporation, NJ,
USA). All other chemicals were purchased from Sigma (St. Louis,
MI, USA) unless otherwise mentioned.
To study the effect of CC-3052 and/or INH on Mtb growth in
vitro, bacterial pellets from mid-log culture were washed with
sterile PBS and resuspended in complete 7H9 media. About
1610
6 CFU/ml of the bacteria in complete 7H9 media was
seeded in to 24 well plates and various concentrations of INH
(0.0125 mg or 0.2 mg per ml), CC-3052 (4 or 40 or 200 mM) or a
combination of both (CC-3052+INH) were added every day up to
4 days. The number of bacterial CFU was enumerated for the
initial inoculum and after every 24 hours of culture by plating
serially diluted bacterial suspensions (treated and untreated) on
7H10 agar plates followed by incubation of the plates at 37uC and
5% CO2 for 4–5 weeks.
Rabbit aerosol infections
A total of 84 male and female, specific pathogen-free, New
Zealand White rabbits of approximately 2.5 kg in weight,
purchased from Millbrook Farms (Millbrook Farms, MA,USA)
wereused forallthe experimentsreportedinthisstudy.Theanimals
were acclimatized for a week after arrival at the PHRI Research
Animal Facility before exposure to aerosol challenge. Groups of 6
rabbits (per round of infection) were infected with Mtb, using a nose-
only aerosol exposure system (CH Technologies, Inc., NJ, USA) as
described earlier [127]. Twelve to twenty-four rabbits were infected
for each experiment. After 3 hours post-exposure, one group of
infected animals were sedated with a combination of Ketamine and
Xylazine and euthanized by Euthasol and necropsy performed to
determine the bacillary load (T=0) implanted in the lungs as
described earlier [128]. For all the experiments, the bacterial
inoculum, exposure time and conditions were standardized so as to
implant approximately 3.2 log10 CFU in the lungs at T=0. Infected
rabbits were housed individually in a BSL-3 facility, with an
unrestricted food and water supply. At defined time points (T=4, 8
and 12 weeks post-infection), groups of 2–4 rabbits, per treatment
and time point, were euthanized and the lung, liver and spleen
aseptically removed and portions of each organs used for CFU
enumeration and isolation of host and bacterial RNA. The tissue
segments for RNA isolation were frozen immediately in liquid
nitrogen and stored at 280uC.
Treatment of Mtb infected rabbits
The Mtb infected rabbits were classified into the following
treatment groups: 1. CC-3052 Treatment. The immune
modulatory drug used in this study, CC-3052, is an analog of
thalidomide. Solutions of CC-3052 were prepared, freshly every
day, in sterile water and administered through gavage at a dose of
25 mg/kg body weight using a flexible rubber feeding tube 5 days
per week. Treatment with CC-3052 started at 4 weeks post-
infection and continued until 12 weeks after infection (8 weeks of
treatment). 2. Isoniazid (INH) Chemotherapy. Freshly
prepared INH, at 25 or 50 mg/kg body weight was administered
to rabbits through oral administration using a flexible rubber
feeding tube 5 days a week. The INH treatment was started at 4
weeks post-infection and continued until 12 weeks after Mtb
infection (8 weeks of treatment). 3. INH plus CC-3052
Combination Therapy. Rabbits were treated with a combina-
tion of INH (50 mg/kg body weight) plus CC-3052 (25 mg/kg
body weight) using a flexible rubber feeding tube 5 days per week.
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continued until 12 weeks after Mtb infection (8 weeks of treatment).
All three treatments were carried out in parallel. One group
each of uninfected and infected but untreated rabbits served as
controls for each time point of the experiment.
Bacillary load estimation
Bacterial loads in the lungs, liver and spleens of the Mtb infected
rabbits were enumerated by CFU assay in respective organs at
each time point of the experiment. Briefly, random portions of
lungs (about 1/3 of the entire lung), liver (about 1/10) and spleen
(about half) tissue homogenates in sterile saline were serially
diluted and plated onto Middlebrook 7H11 agar plates (Difco, MI,
USA) with or without INH supplement (0.2 mg/ml). The plates
were incubated at 37uC for 4 to 5 weeks. Colonies were counted,
and results were calculated for total numbers of CFU in the whole
organ.
Host and mycobacterial total RNA isolation
Total RNA of the host and Mtb were isolated from the lung
tissues of all four groups of rabbit (infected, infected and CC-3052-
, INH- or INH+CC-3052- treated and uninfected) at each time
point of necropsy (T=0, 4, 8 and 12 weeks post-infection). Tissue
sections from each rabbit were processed separately for host and
bacterial RNA extraction. To prepare host RNA, lung tissue slices
were homogenized in 10 volumes (wt/vol) of TRIzol (Invitrogen,
CA, USA) using a PolyTron homogenizer (Kinematica, Lucerne,
Switzerland), and extracted with 0.3 vol (vol/vol) of chloroform.
The mixture was centrifuged at 13,000 rpm for 20 minutes at 4uC
and the cleared supernatant was added to an equal volume of
precipitation solution (Macherey-Nagel, GmbH) and eluted
through the NucleoSpin kit as per the manufacturer’s protocol
(Macherey-Nagel, GmbH). For bacterial total RNA isolation from
infected rabbit lungs, a modified differential lysis method was used
[129]. Briefly, the tissue sections were homogenized in 10 volumes
of sterile 0.01% SDS solution, followed by centrifugation at
13,000 rpm for 20 minutes at 15uC to pellet the bacteria. The
bacterial pellet was resuspended in 10 volume of TRIzol (wt/vol)
and the mixture was subjected to bead beating with Ribo-lyser
(MP Biosciences, OK, USA) for 2 minutes in 30-seconds pulses
with 1-minute ice-incubation in between the pulses. The lysate was
extracted with equal volume of chloroform (vol/vol) followed by
centrifugation and the cleared supernatant was eluted using
NucleoSpin kit as per the manufacturer’s protocol (Macherey-
Nagel, GmbH). Both host and bacterial RNA were subjected to
DNase I digestion before final purification through RNeasy mini
kit (Qiagen, MD, USA). The quantity and quality of the total
RNA was estimated by NanoDrop (NanoDrop Products, DE,
USA) and agarose gel electrophoresis as reported elsewhere [130].
Rabbit microarray analysis
The rabbit microarray slides and the recommended reagents
were purchased from Agilent Technologies (Agilent Technologies,
CA, USA). According to the manufacturer, each rabbit micro-
array slide contains quadruplicates of 43,604 probes (4 arrays per
slide) of rabbit genome, derived from public domain databases,
corresponding to 43,604 open reading frames (ORFs). The total
lung RNA from individual rabbits (2–4 animals per time point per
group) was processed separately for each microarray experiment.
Dye-swap was done for every group, to avoid dye bias during
cDNA labeling, hybridization and post-hybridization procedures.
The conditions for cDNA synthesis, labeling and hybridization
were according to the standard operating protocol of the Center
for Advanced Genomics of PHRI (refer ,http://www.cag.icph.
org/downloads_page.htm.). For the 4 weeks time point, the gene
expression values of the Mtb infected rabbits were calculated
relative to uninfected rabbits (Infected vs. Uninfected) and for all
other time points, the gene expression values of CC-3052 treated
rabbits were calibrated against untreated (but Mtb infected) rabbits
at the same time point (CC-3052 treated vs. untreated). The slides
were scanned and analyzed by Agilent Scanner and Feature
Extraction Software (Agilent Technologies, CA, USA) and the
acquired data was loaded into Partek Genomics Suite (PARTEK,
MO, USA) for further analysis after appropriate statistical analysis
to adjust for the errors. A 2.0 fold difference in expression value
and a p value of less than 0.05 was set as cut-off to select
differentially expressed genes between various comparison groups.
The selected list of differentially expressed rabbit genes from
PARTEK Genomics Suite was further analyzed for functional
classification including derivation of networks and pathways using
Ingenuity Pathway Analysis (IPA) software (Ingenuity Pathway
Analysis, CA, USA). Since the information on the functional
characterization of rabbit genes is currently unavailable with any
of the commercial software including IPA, we used the gene
information from human, mouse and rat database, from various
microarray platforms, available in IPA. We searched the IPA
knowledge base for conserved homologous of rabbit genes that
perform similar functions and mostly share common pathways,
across the 3 different species (mouse, rat and human). The filtered
list of rabbit genes, containing ‘‘pathway eligible genes’’ was
classified according to their functions in specific pathways and
used to construct corresponding networks in IPA. The complete
list of rabbit genes differentially expressed by CC-3052 treatment
has been submitted to the GEO database (GSE27992).
Quantitative Real Time PCR Analysis (qRT-PCR)
Total RNA of the host and Mtb, isolated from the uninfected/
infected rabbit lungs were subjected to cDNA synthesis using
Sprint RT Complete kit as described by the manufacturer
(Clontech, CA, USA). The cDNA was amplified with gene specific
primers and SYBR green mix as per the manufacturer’s
instructions (Clontech, CA, USA) in a MxPro4000 real time
PCR machine (Stratagene, CA, USA). The SYBR green qRT-
PCR mix also contains ROX as an internal reference dye. The
primers for specific rabbit and Mtb genes were designed using
Clone Manager Suite (Sci-Ed software, NC, USA). The DNA (for
Mtb) and mRNA (for rabbit) sequences of specific Mtb and rabbit
genes were obtained from Tuberculist (for Mtb genes) or GenBank
(for rabbit genes) data base. The DNA sequences of the primers
used for qRT-PCR can be found in Table S1 and S2. The
threshold cycle (Ct) for each amplified target gene was calculated
using MxPro4000 software (Stratagene, CA, USA). Uniform
baseline fluorescence was set for all the genes in each experiment
and across different experiments. The Mtb gene for 16S rRNA and
the transcripts for rabbit GAPDH gene were used to normalize the
Ct values of the target genes. Fold change was calculated using the
formula 2
2DDCt and represented either as absolute transcript levels
or as relative expression after normalization to uninfected or
untreated groups. The experiments were repeated at least 3 times
with RNA samples from two to four animals per group per time
point per treatment group.
Isoniazid measurement in rabbit plasma
The concentration of INH in the plasma of Mtb infected and
treated rabbits were measured using Sciex API4000 (Applied
Biosystems, CA, USA) mass spectrometer coupled to Symbiosis
Pharma HPLC system (Spark Holland B.V, The Netherlands).
Briefly, one part of the plasma or homogenized lung tissue was
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acetic acid. Ten microliter of the supernatant was injected into a
Phenomenex Gemini C6-Phenyl column (4.66150 mm) (Phenom-
enex, CA, USA) and eluted with a gradient of mobile phase A
(0.2% acetic acid in deionized water) and B (0.2% acetic acid in
methanol) at a flow rate of 1 ml/min. Presence of the INH
analytes and quantification of drug levels were performed by
monitoring multiple reactions of parent/daughter transitions in
electro-spray positive ionization mode. The test samples, standards
and quality control samples were spiked with Warfarin, which was
used as an internal standard. The calibration curve was designed
to cover the expected concentration range (10.2 ng/ml to
10.4 mg/ml) of samples delivered and was derived from standard
solutions of INH. The data obtained was processed using Analyst
software v 1.4.2 (Applied Biosystems, CA, USA) and regression for
pharmacokinetic parameters was performed as non-compartmen-
tal analysis using WinNonLin 5.0 (Pharsight, CA, USA).
Statistical analysis
The independent Student t-test or the Mann-Whitney test for
nonparametric independent data was used for analysis (SPSS
software). p#0.05 was considered significant for all the experi-
ments.
Supporting Information
Figure S1 Effect of CC-3052 on the expression of
dormancy-related genes of Mtb. Log phase Mtb culture
was exposed to 4uM of CC-3052 for 24 hours and total bacterial
RNA was isolated. The untreated culture was added with
equimolar amount of the vehicle (DMSO) and processed similarly
for RNA isolation. Results shown are mean 6 standard deviation
from at least 2 experiments done in duplicate. No statistically
significant difference in the dormancy related Mtb gene expression
was observed between untreated and CC-3052 treated bacteria.
(TIF)
Figure S2 The effect of CC-3052 and INH on the growth
of Mtb in vitro. The number of Mtb CFU (in log10 scale) during
treatment with various concentrations of CC-3052 (A) or INH (B)
or both (C) up to 4 days in Middlebrook 7H9 liquid media. The
concentrations of CC-3052 are in micromoles and of INH are in
micrograms; UT-untreated. Results shown are mean 6 standard
deviation from at least 2 experiments done in triplicate (total of at
least 6 data points).
(TIF)
Table S1 List of Mtb primers used in qRT-PCR
experiments. The DNA sequences of listed Mtb genes were
obtained from Tuberculist (http://genolist.pasteur.fr/Tubercu-
List/) using the gene names to search for the sequence.
(XLS)
Table S2 List of rabbit primers used in qRT-PCR
experiments. The DNA sequences of listed rabbit genes were
obtained from GenBank (http://www.ncbi.nlm.nih.gov/genbank/)
using the gene names to search for the sequence.
(XLS)
Acknowledgments
We acknowledge Drs. Claudia Manca, Issar Smith, Barun Mathema,
Bavesh Kana and Helena Boshoff for their interest and valuable
suggestions. We would like to thank Peiting Zeng, Hui Qing Ang and
Anne Goh of Novartis Institute for Tropical Disease, Singapore, for their
help with the INH estimation studies. We thank the Center for Advanced
Genomics (CAG) of PHRI for help with the microarray work and F.
Sabrina Dalton for assistance in preparing the manuscript.
Author Contributions
Conceived and designed the experiments: SS DF LT GK. Performed the
experiments: SS PO LT GY MK VD BP. Analyzed the data: SS GK.
Contributed reagents/materials/analysis tools: VD GM. Wrote the paper:
SS DF LT GK.
References
1. Dye C, Williams BG (2010) The population dynamics and control of
tuberculosis. Science 328: 856–861.
2. de Chastellier C (2009) The many niches and strategies used by pathogenic
mycobacteria for survival within host macrophages. Immunobiology 214:
526–542.
3. Saunders BM, Britton WJ (2007) Life and death in the granuloma:
immunopathology of tuberculosis. Immunol Cell Biol 85: 103–111.
4. Cosma CL, Sherman DR, Ramakrishnan L (2003) The secret lives of the
pathogenic mycobacteria. Annu Rev Microbiol 57: 641–676.
5. Pieters J (2008) Mycobacterium tuberculosis and the macrophage: maintaining
a balance. Cell Host Microbe 3: 399–407.
6. Jordao L, Bleck CK, Mayorga L, Griffiths G, Anes E (2008) On the killing of
mycobacteria by macrophages. Cell Microbiol 10: 529–548.
7. Paige C, Bishai WR (2009) Penitentiary or penthouse condo: the tuberculous
granuloma from the microbe’s point of view. Cell Microbiol 12: 301–309.
8. Stokes RW, Waddell SJ (2009) Adjusting to a new home: Mycobacterium
tuberculosis gene expression in response to an intracellular lifestyle. Future
Microbiol 4: 1317–1335.
9. Steinberg BE, Grinstein S (2008) Pathogen destruction versus intracellular
survival: the role of lipids as phagosomal fate determinants. J Clin Invest 118:
2002–2011.
10. Chan J, Flynn J (2004) The immunological aspects of latency in tuberculosis.
Clin Immunol 110: 2–12.
11. Flannagan RS, Cosio G, Grinstein S (2009) Antimicrobial mechanisms of
phagocytes and bacterial evasion strategies. Nat Rev Microbiol 7: 355–366.
12. Rohde KH, Abramovitch RB, Russell DG (2007) Mycobacterium tuberculosis
invasion of macrophages: linking bacterial gene expression to environmental
cues. Cell Host Microbe 2: 352–364.
13. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, et al. (2003)
Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophag-
es: Insights into the Phagosomal Environment. J Exp Med 198: 693–704.
14. Dutta NK, Mehra S, Didier PJ, Roy CJ, Doyle LA, et al. (2010) Genetic
requirements for the survival of tubercle bacilli in primates. J Infect Dis 201:
1743–1752.
15. Tailleux L, Waddell SJ, Pelizzola M, Mortellaro A, Withers M, et al. (2008)
Probing host pathogen cross-talk by transcriptional profiling of both
Mycobacterium tuberculosis and infected human dendritic cells and macro-
phages. PLoS One 3: e1403.
16. Hampshire T, Soneji S, Bacon J, James BW, Hinds J, et al. (2004) Stationary
phase gene expression of Mycobacterium tuberculosis following a progressive
nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb) 84:
228–238.
17. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19:
93–129.
18. Koul A, Herget T, Klebl B, Ullrich A (2004) Interplay between mycobacteria
and host signalling pathways. Nat Rev Microbiol 2: 189–202.
19. Sahiratmadja E, Alisjahbana B, de Boer T, Adnan I, Maya A, et al. (2007)
Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma
interferon receptor signaling integrity correlate with tuberculosis disease activity
and response to curative treatment. Infect Immun 75: 820–829.
20. Salgame P (2005) Host innate and Th1 responses and the bacterial factors that
control Mycobacterium tuberculosis infection. Curr Opin Immunol 17:
374–380.
21. MacMicking JD (2009) Recognizing macrophage activation and host defense.
Cell Host Microbe 5: 405–407.
22. Liu PT, Modlin RL (2008) Human macrophage host defense against
Mycobacterium tuberculosis. Curr Opin Immunol 20: 371–376.
23. Ehrt S, Schnappinger D (2009) Mycobacterial survival strategies in the
phagosome: defence against host stresses. Cell Microbiol 11: 1170–1178.
24. Quesniaux VF, Jacobs M, Allie N, Grivennikov S, Nedospasov SA, et al. (2010)
TNF in host resistance to tuberculosis infection. Curr Dir Autoimmun 11:
157–179.
25. Ly LH, McMurray DN (2009) The Yin-Yang of TNFalpha in the guinea pig
model of tuberculosis. Indian J Exp Biol 47: 432–439.
26. Bekker LG, Freeman S, Murray PJ, Ryffel B, Kaplan G (2001) TNF-alpha
controls intracellular mycobacterial growth by both inducible nitric oxide
synthase-dependent and inducible nitric oxide synthase-independent pathways.
J Immunol 166: 6728–6734.
Adjunctive Immune Modulation Improves TB Therapy
PLoS Pathogens | www.plospathogens.org 17 September 2011 | Volume 7 | Issue 9 | e100226227. Hao S, Baltimore D (2009) The stability of mRNA influences the temporal
order of the induction of genes encoding inflammatory molecules. Nat
Immunol 10: 281–288.
28. Botha T, Ryffel B (2003) Reactivation of latent tuberculosis infection in TNF-
deficient mice. J Immunol 171: 3110–3118.
29. Bekker LG, Haslett P, Maartens G, Steyn L, Kaplan G (2000) Thalidomide-
induced antigen-specific immune stimulation in patients with human
immunodeficiency virus type 1 and tuberculosis. J Infect Dis 181: 954–965.
30. Kast RE (2000) Tumor necrosis factor has positive and negative self regulatory
feed back cycles centered around cAMP. Int J Immunopharmacol 22:
1001–1006.
31. Zidek Z (1999) Adenosine - cyclic AMP pathways and cytokine expression. Eur
Cytokine Netw 10: 319–328.
32. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, et al. (1998)
Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10
synthesis and concurrent suppression of TNF production. J Leukoc Biol 63:
101–107.
33. Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M (2008) Cyclic
AMP: master regulator of innate immune cell function. Am J Respir Cell Mol
Biol 39: 127–132.
34. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, et al. (1996) Evidence
that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation
from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4
conformer. Br J Pharmacol 118: 649–658.
35. Souness JE, Aldous D, Sargent C (2000) Immunosuppressive and anti-
inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors.
Immunopharmacology 47: 127–162.
36. Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R (2008) Insights
into the regulation of TNF-alpha production in human mononuclear cells: the
effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 63:
321–328.
37. Lee TW, Fedorak RN (2010) Tumor necrosis factor-alpha monoclonal
antibodies in the treatment of inflammatory bowel disease: clinical practice
pharmacology. Gastroenterol Clin North Am 39: 543–557.
38. Taylor PC (2010) Pharmacology of TNF blockade in rheumatoid arthritis and
other chronic inflammatory diseases. Curr Opin Pharmacol 10: 308–315.
39. Murdaca G, Colombo BM, Puppo F (2009) Anti-TNF-alpha inhibitors: a new
therapeutic approach for inflammatory immune-mediated diseases: an update
upon efficacy and adverse events. Int J Immunopathol Pharmacol 22: 557–565.
40. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide
selectively inhibits tumor necrosis factor alpha production by stimulated human
monocytes. J Exp Med 173: 699–703.
41. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, et al. (1993)
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by
enhancing mRNA degradation. J Exp Med 177: 1675–1680.
42. Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, et al.
(1995) Thalidomide treatment reduces tumor necrosis factor alpha production
and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1:
384–397.
43. Corral LG, Kaplan G (1999) Immunomodulation by thalidomide and
thalidomide analogues. Ann Rheum Dis 58(Suppl 1): I107–113.
44. Marriott JB, Muller G, Stirling D, Dalgleish AG (2001) Immunotherapeutic
and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 1:
675–682.
45. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, et al. (2004) Phase I
study to determine the safety, tolerability and immunostimulatory activity of
thalidomide analogue CC-5013 in patients with metastatic malignant
melanoma and other advanced cancers. Br J Cancer 90: 955–961.
46. Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, et al. (1998)
CC-3052: a water-soluble analog of thalidomide and potent inhibitor of
activation-induced TNF-alpha production. J Immunol 161: 4236–4243.
47. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, et al. (1999)
Differential cytokine modulation and T cell activation by two distinct classes of
thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol
163: 380–386.
48. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, et al. (2002)
Thalidomide and its analogues have distinct and opposing effects on TNF-
alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Clin Exp Immunol 130: 75–84.
49. Koo MS, Manca C, Yang G, O’Brien P, Sung N, et al. (2011)
Phosphodiesterase 4 inhibition reduces innate immunity and improves
isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected
mice. PLoS One 6: e17091.
50. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, et al. (2000) A
multicentre study of the early bactericidal activity of anti-tuberculosis drugs.
J Antimicrob Chemother 45: 859–870.
51. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of
tuberculosis undertaken by the British Medical Research Council tuberculosis
units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis
3: S231–279.
52. Mitchison DA (2003) Role of isoniazid in once-weekly rifapentine treatment of
pulmonary tuberculosis. Am J Respir Crit Care Med 167: 1298–1299.
53. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, et al. (2003) Low
isoniazid concentrations and outcome of tuberculosis treatment with once-
weekly isoniazid and rifapentine. Am J Respir Crit Care Med 167: 1341–1347.
54. Betts JC, McLaren A, Lennon MG, Kelly FM, Lukey PT, et al. (2003)
Signature gene expression profiles discriminate between isoniazid-, thiolacto-
mycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob Agents
Chemother 47: 2903–2913.
55. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, et al. (2004) The
transcriptional responses of Mycobacterium tuberculosis to inhibitors of
metabolism: novel insights into drug mechanisms of action. J Biol Chem 279:
40174–40184.
56. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, et al. (1999)
Exploring drug-induced alterations in gene expression in Mycobacterium
tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A 96:
12833–12838.
57. Karakousis PC, Williams EP, Bishai WR (2008) Altered expression of isoniazid-
regulated genes in drug-treated dormant Mycobacterium tuberculosis.
J Antimicrob Chemother 61: 323–331.
58. JoAnne L, Flynn LT, Angelo Izzo, Gilla Kaplan, eds (2008) Experimental
Animal Models of Tuberculosis. KGaAWeinheim: Wiley-VCH Verlag
GmBH&Co. pp 389–426.
59. Lee BY, Jethwaney D, Schilling B, Clemens DL, Gibson BW, et al. The
Mycobacterium bovis bacille Calmette-Guerin phagosome proteome. Mol Cell
Proteomics 9: 32–53.
60. Ma Y, Liu H, Tu-Rapp H, Thiesen HJ, Ibrahim SM, et al. (2004) Fas ligation
on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes
chronic inflammation. Nat Immunol 5: 380–387.
61. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, et al. (2008) Tuberculous
granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect
Immun 76: 2333–2340.
62. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, et al. (2003) Rv3133c/
dosR is a transcription factor that mediates the hypoxic response of
Mycobacterium tuberculosis. Mol Microbiol 48: 833–843.
63. Bartek IL, Rutherford R, Gruppo V, Morton RA, Morris RP, et al. (2009) The
DosR regulon of M. tuberculosis and antibacterial tolerance. Tuberculosis
(Edinb) 89: 310–316.
64. Homolka S, Niemann S, Russell DG, Rohde KH (2010) Functional genetic
diversity among Mycobacterium tuberculosis complex clinical isolates:
delineation of conserved core and lineage-specific transcriptomes during
intracellular survival. PLoS Pathog 6: e1000988.
65. Sohaskey CD, Wayne LG (2003) Role of narK2X and narGHJI in hypoxic
upregulation of nitrate reduction by Mycobacterium tuberculosis. J Bacteriol
185: 7247–7256.
66. Humpel A, Gebhard S, Cook GM, Berney M (2010) The SigF regulon in
Mycobacterium smegmatis reveals roles in adaptation to stationary phase, heat,
and oxidative stress. J Bacteriol 192: 2491–2502.
67. Schnappinger D, Schoolnik GK, Ehrt S (2006) Expression profiling of host
pathogen interactions: how Mycobacterium tuberculosis and the macrophage
adapt to one another. Microbes Infect 8: 1132–1140.
68. Waddell SJ, Stabler RA, Laing K, Kremer L, Reynolds RC, et al. (2004) The
use of microarray analysis to determine the gene expression profiles of
Mycobacterium tuberculosis in response to anti-bacterial compounds. Tuber-
culosis (Edinb) 84: 263–274.
69. Kaplan G, Tsenova L (2010) Pulmonary Tuberculosis in the Rabbit. In: Leong
F.J DV, Dick T, eds. A color atlas of comparative pathology of pulmonary
tuberculosis. Singapore: CRC Press. pp 107–130.
70. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC,
Nuermberger EL, et al. (2004) Dormancy phenotype displayed by extracellular
Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med
200: 647–657.
71. Jindani A, Aber VR, Edwards EA, Mitchison DA (1980) The early bactericidal
activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis
121: 939–949.
72. Vilcheze C, Jacobs WR, Jr. (2007) The mechanism of isoniazid killing: clarity
through the scope of genetics. Annu Rev Microbiol 61: 35–50.
73. Russell DG (2001) Mycobacterium tuberculosis: here today, and here
tomorrow. Nat Rev Mol Cell Biol 2: 569–577.
74. Beavo JA, Conti M, Heaslip RJ (1994) Multiple cyclic nucleotide phosphodi-
esterases. Mol Pharmacol 46: 399–405.
75. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide
phosphodiesterases: essential components in cyclic nucleotide signaling. Annu
Rev Biochem 76: 481–511.
76. Shepherd MC, Baillie GS, Stirling DI, Houslay MD (2004) Remodelling of the
PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage
differentiation of human U937 cells. Br J Pharmacol 142: 339–351.
77. Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai WR (2009) Cyclic AMP
intoxication of macrophages by a Mycobacterium tuberculosis adenylate
cyclase. Nature 460: 98–102.
78. Tasken K, Aandahl EM (2004) Localized effects of cAMP mediated by distinct
routes of protein kinase A. Physiol Rev 84: 137–167.
79. Bengis-Garber C, Gruener N (1996) Protein kinase A downregulates the
phosphorylation of p47 phox in human neutrophils: a possible pathway for
inhibition of the respiratory burst. Cell Signal 8: 291–296.
Adjunctive Immune Modulation Improves TB Therapy
PLoS Pathogens | www.plospathogens.org 18 September 2011 | Volume 7 | Issue 9 | e100226280. Kalamidas SA, Kuehnel MP, Peyron P, Rybin V, Rauch S, et al. (2006) cAMP
synthesis and degradation by phagosomes regulate actin assembly and fusion
events: consequences for mycobacteria. J Cell Sci 119: 3686–3694.
81. Lin PL, Plessner HL, Voitenok NN, Flynn JL (2007) Tumor necrosis factor and
tuberculosis. J Investig Dermatol Symp Proc 12: 22–25.
82. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:
499–511.
83. Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their
role in innate and adaptive immunity. Trends Immunol 25: 280–288.
84. Ly LH, Jeevan A, McMurray DN (2009) Neutralization of TNFalpha alters
inflammation in guinea pig tuberculous pleuritis. Microbes Infect 11: 680–688.
85. Roberts EA, Chua J, Kyei GB, Deretic V (2006) Higher order Rab
programming in phagolysosome biogenesis. J Cell Biol 174: 923–929.
86. Thuong NT, Dunstan SJ, Chau TT, Thorsson V, Simmons CP, et al. (2008)
Identification of tuberculosis susceptibility genes with human macrophage gene
expression profiles. PLoS Pathog 4: e1000229.
87. Volpe E, Cappelli G, Grassi M, Martino A, Serafino A, et al. (2006) Gene
expression profiling of human macrophages at late time of infection with
Mycobacterium tuberculosis. Immunology 118: 449–460.
88. Shui W, Gilmore SA, Sheu L, Liu J, Keasling JD, et al. (2009) Quantitative
proteomic profiling of host-pathogen interactions: the macrophage response to
Mycobacterium tuberculosis lipids. J Proteome Res 8: 282–289.
89. Rohde K, Yates RM, Purdy GE, Russell DG (2007) Mycobacterium
tuberculosis and the environment within the phagosome. Immunol Rev 219:
37–54.
90. Cappelli G, Volpe E, Grassi M, Liseo B, Colizzi V, et al. (2006) Profiling of
Mycobacterium tuberculosis gene expression during human macrophage
infection: upregulation of the alternative sigma factor G, a group of
transcriptional regulators, and proteins with unknown function. Res Microbiol
157: 445–455.
91. Deb C, Lee CM, Dubey VS, Daniel J, Abomoelak B, et al. (2009) A novel in
vitro multiple-stress dormancy model for Mycobacterium tuberculosis gener-
ates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 4: e6077.
92. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, et al. (2003)
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment
with failed immunity. Infect Immun 71: 7099–7108.
93. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, et al.
(2003) Inhibition of respiration by nitric oxide induces a Mycobacterium
tuberculosis dormancy program. J Exp Med 198: 705–713.
94. Sirakova TD, Dubey VS, Deb C, Daniel J, Korotkova TA, et al. (2006)
Identification of a diacylglycerol acyltransferase gene involved in accumulation
of triacylglycerol in Mycobacterium tuberculosis under stress. Microbiology
152: 2717–2725.
95. Shiloh MU, Manzanillo P, Cox JS (2008) Mycobacterium tuberculosis senses
host-derived carbon monoxide during macrophage infection. Cell Host
Microbe 3: 323–330.
96. Primm TP, Andersen SJ, Mizrahi V, Avarbock D, Rubin H, et al. (2000) The
stringent response of Mycobacterium tuberculosis is required for long-term
survival. J Bacteriol 182: 4889–4898.
97. Klinkenberg LG, Lee JH, Bishai WR, Karakousis PC (2011) The stringent
response is required for full virulence of Mycobacterium tuberculosis in guinea
pigs. J Infect Dis 202: 1397–1404.
98. Rosenkrands I, Slayden RA, Crawford J, Aagaard C, Barry CE, 3rd, et al.
(2002) Hypoxic response of Mycobacterium tuberculosis studied by metabolic
labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol
184: 3485–3491.
99. Converse PJ, Karakousis PC, Klinkenberg LG, Kesavan AK, Ly LH, et al.
(2009) Role of the dosR-dosS two-component regulatory system in Mycobac-
terium tuberculosis virulence in three animal models. Infect Immun 77:
1230–1237.
100. Kesavan AK, Brooks M, Tufariello J, Chan J, Manabe YC (2009) Tuberculosis
genes expressed during persistence and reactivation in the resistant rabbit
model. Tuberculosis (Edinb) 89: 17–21.
101. Sachdeva P, Misra R, Tyagi AK, Singh Y (2009) The sigma factors of
Mycobacterium tuberculosis: regulation of the regulators. FEBS J 277:
605–626.
102. Rao V, Fujiwara N, Porcelli SA, Glickman MS (2005) Mycobacterium
tuberculosis controls host innate immune activation through cyclopropane
modification of a glycolipid effector molecule. J Exp Med 201: 535–543.
103. Rao V, Gao F, Chen B, Jacobs WR, Jr., Glickman MS (2006) Trans-
cyclopropanation of mycolic acids on trehalose dimycolate suppresses
Mycobacterium tuberculosis -induced inflammation and virulence. J Clin
Invest 116: 1660–1667.
104. Leistikow RL, Morton RA, Bartek IL, Frimpong I, Wagner K, et al. (2009) The
Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and
enables rapid recovery from nonrespiring dormancy. J Bacteriol 192:
1662–1670.
105. Chauhan S, Sharma D, Singh A, Surolia A, Tyagi JS (2011) Comprehensive
insights into Mycobacterium tuberculosis DevR (DosR) regulon activation
switch. Nucleic Acids Res. E-pub ahead of print. doi:10.1093/nar/gkr37.
106. Saint-Joanis B, Souchon H, Wilming M, Johnsson K, Alzari PM, et al. (1999)
Use of site-directed mutagenesis to probe the structure, function and isoniazid
activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis.
Biochem J 338(Pt 3): 753–760.
107. Parikh SL, Xiao G, Tonge PJ (2000) Inhibition of InhA, the enoyl reductase
from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39:
7645–7650.
108. Wengenack NL, Jensen MP, Rusnak F, Stern MK (1999) Mycobacterium
tuberculosis KatG is a peroxynitritase. Biochem Biophys Res Commun 256:
485–487.
109. Timmins GS, Deretic V (2006) Mechanisms of action of isoniazid. Mol
Microbiol 62: 1220–1227.
110. Fontan PA, Aris V, Alvarez ME, Ghanny S, Cheng J, et al. (2008)
Mycobacterium tuberculosis sigma factor E regulon modulates the host
inflammatory response. J Infect Dis 198: 877–885.
111. Morris RP, Nguyen L, Gatfield J, Visconti K, Nguyen K, et al. (2005) Ancestral
antibiotic resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A
102: 12200–12205.
112. Nguyen L, Thompson CJ (2006) Foundations of antibiotic resistance in
bacterial physiology: the mycobacterial paradigm. Trends Microbiol 14:
304–312.
113. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, et al. (2011)
Drug tolerance in replicating mycobacteria mediated by a macrophage-
induced efflux mechanism. Cell 145: 39–53.
114. Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, et al. (2011)
Microarray analysis of efflux pump genes in multidrug-resistant Mycobacte-
rium tuberculosis during stress induced by common anti-tuberculous drugs.
Microb Drug Resist 16: 21–28.
115. Vilcheze C, Baughn AD, Tufariello J, Leung L, Kuo M, et al. (2011) Novel
inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic
and anaerobic conditions. Antimicrob Agents Chemother 55: 3889–98.
116. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, et al. (1995) Tumor
necrosis factor-alpha is required in the protective immune response against
Mycobacterium tuberculosis in mice. Immunity 2: 561–572.
117. Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, et al. (2008) Tumor
necrosis factor blockade in chronic murine tuberculosis enhances granuloma-
tous inflammation and disorganizes granulomas in the lungs. Infect Immun 76:
916–926.
118. Bernstein DM, Laney C, Morris EK, Loftus EF (2005) False beliefs about
fattening foods can have healthy consequences. Proc Natl Acad Sci U S A 102:
13724–13731.
119. Lynch MJ, Hill EV, Houslay MD (2006) Intracellular targeting of
phosphodiesterase-4 underpins compartmentalized cAMP signaling. Curr
Top Dev Biol 75: 225–259.
120. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, et al. (2007)
Pulmonary impairment after tuberculosis. Chest 131: 1817–1824.
121. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS (2006) Tumor-
necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect
Dis 194: 486–492.
122. La Maestra L, Zaninoni A, Marriott JB, Lazzarin A, Dalgleish AG, et al. (2000)
The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis
factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in
vitro. Clin Exp Immunol 119: 123–129.
123. Guckian M, Dransfield I, Hay P, Dalgleish AG (2000) Thalidomide analogue
CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin Exp Immunol 121:
472–479.
124. Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155: 308–315.
125. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and
its IMiD derivatives as anticancer agents. Nat Rev Cancer 4: 314–322.
126. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, et al. (2010)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflam-
matory activity in vitro and in a model of psoriasis. Br J Pharmacol 159:
842–855.
127. Tsenova L, Bergtold A, Freedman VH, Young RA, Kaplan G (1999) Tumor
necrosis factor alpha is a determinant of pathogenesis and disease progression
in mycobacterial infection in the central nervous system. Proc Natl Acad
Sci U S A 96: 5657–5662.
128. Tsenova L, Sokol K, Freedman VH, Kaplan G (1998) A combination of
thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-
associated death. J Infect Dis 177: 1563–1572.
129. Talaat AM, Lyons R, Howard ST, Johnston SA (2004) The temporal
expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl
Acad Sci U S A 101: 4602–4607.
130. Subbian S, Mehta PK, Cirillo SL, Cirillo JD (2007) The Mycobacterium
marinum mel2 locus displays similarity to bacterial bioluminescence systems
and plays a role in defense against reactive oxygen and nitrogen species. BMC
Microbiol 7: 4.
Adjunctive Immune Modulation Improves TB Therapy
PLoS Pathogens | www.plospathogens.org 19 September 2011 | Volume 7 | Issue 9 | e1002262